SGD Pharma, a global producer of pharmaceutical glass primary packaging, is showcasing its latest innovations in molded and tubular glass at Pharmapack Europe 2026 in Paris. On booth 4C11 & 4C17, the company will demonstrate new solutions designed to enhance drug integrity, patient safety and operational efficiency, alongside its continued commitment to decarbonisation and sustainable manufacturing.

The company will present its complete glass packaging portfolio for the first time, including tubular products from the Alphial acquisition, which strengthens its European manufacturing footprint. Key products on display include SEALIAN, a high-performance internal surface treatment providing enhanced chemical durability for sensitive drugs, and IDENCY, premium vials that combine chemical and mechanical resistance while maintaining compatibility with standard tubular glass filling lines.

SGD Pharma will also highlight Sterinity EZ-fill, a ready-to-use platform aimed at speeding time-to-market and improving operational flexibility, as well as Alphial tubular products such as ampoules, vials and RTU solutions made in Italy. Other innovations include Velocity vials developed with Corning to enhance fill and finish efficiency, advanced external treatments through PROSEAL+ for moisture and oxygen protection, and Lab Services offering expertise in glass packaging science and analytical testing.

Olivier Rousseau, CEO of SGD Pharma, said: “At Pharmapack 2026, we are proud to demonstrate how innovation and sustainability go hand in hand in shaping the future of pharmaceutical glass. As a recognized leader in sustainable glass manufacturing, we have again earned an EcoVadis platinum medal for our continued progress. We are committed to decarbonizing the Pharma Glass Industry faster than anyone else and we are working hard, and investing a lot, to do even better and go further than ever before to help our customers deliver on their own decarbonisation commitments.”

SGD Pharma has been awarded EcoVadis Platinum status with a score of 90, recognising its leadership in sustainable performance among pharmaceutical glass manufacturers. The company’s Science Based Targets initiative (SBTi)-validated roadmap sets ambitious goals to cut carbon emissions by 42% by 2030 and 65% by 2040 compared to 2022 levels, supported by energy efficiency investments, responsible sourcing, and workforce inclusion.

The integration of Alphial’s Italian sites expands SGD Pharma’s capability in tubular glass, enabling faster delivery, increased capacity and improved responsiveness, particularly for high-value biopharmaceutical applications. This complements its global leadership in molded glass and supports customers across ampoules, vials and RTU formats.